<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE328nnn/GSE328958/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Genomics</omics_type><species>Homo sapiens</species><gds_type>Genome binding/occupancy profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE328958</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>A conformation-sensitive product inhibitor of HDAC1/2 potentiates WNT/β-catenin signaling [ChIP-seq]</name><description>Pharmacological enhancement of WNT/β-catenin signaling holds promises for tissue repair and regeneration. Here, we identify WNA1, an isoxazole-based small molecule, as a potent activator of WNT/β-catenin signaling. WNA1 stimulates β-catenin signaling in different cellular contexts, and this activity requires production of endogenous WNT. In vivo, WNA1 promotes skin hair growth, consistent with the established role of β-catenin signaling in hair follicle development. Intriguingly, WNA1 increases histone acetylation with minimal activity on uncomplexed recombinant histone deacetylases (HDACs), while conventional HDAC inhibitors exhibit minimal β-catenin-stabilizing activity. We demonstrate that β-catenin signaling is repressed by the HDAC1/2-containing NuRD complex, and that WNA1 enhances β-catenin signaling through selectively inhibiting HDAC1/2. Structural and biochemical analyses reveal that WNA1 is hydrolyzed by the HDAC1-MTA1 complex, and its product is trapped in the foot-pocket of HDAC1 in an InsP6-dependent manner. HDAC1 mutants with reduced foot-pocket abrogate WNA1-induced histone acetylation and β-catenin accumulation. These findings establish WNA1 as a conformation-sensitive, foot-pocket-anchored product inhibitor that selectively targets complex-bound HDAC1/2. Our study reveals a unique mechanism for HDAC1/2 inhibition and WNT potentiation, paving the way for therapeutic applications.</description><dates><publication>2026/09/01</publication></dates><accession>GSE328958</accession><cross_references><GSM>GSM9694879</GSM><GSM>GSM9694878</GSM><GSM>GSM9694886</GSM><GSM>GSM9694885</GSM><GSM>GSM9694888</GSM><GSM>GSM9694887</GSM><GSM>GSM9694882</GSM><GSM>GSM9694881</GSM><GSM>GSM9694884</GSM><GSM>GSM9694883</GSM><GSM>GSM9694880</GSM><GSM>GSM9694889</GSM><GSM>GSM9694869</GSM><GSM>GSM9694875</GSM><GSM>GSM9694874</GSM><GSM>GSM9694896</GSM><GSM>GSM9694877</GSM><GSM>GSM9694876</GSM><GSM>GSM9694871</GSM><GSM>GSM9694893</GSM><GSM>GSM9694892</GSM><GSM>GSM9694870</GSM><GSM>GSM9694895</GSM><GSM>GSM9694873</GSM><GSM>GSM9694894</GSM><GSM>GSM9694872</GSM><GSM>GSM9694891</GSM><GSM>GSM9694890</GSM><GPL>16791</GPL><GSE>328958</GSE><taxon>Homo sapiens</taxon></cross_references></HashMap>